## SENATE STATE OF MINNESOTA EIGHTY-NINTH SESSION

A bill for an act

relating to human services; requiring medical assistance to cover medically necessary gender dysphoria and certain prescribed drugs for treatment of gender

S.F. No. 2141

(SENATE AUTHORS: DIBBLE, Eaton, Sheran, Marty and Pappas)

DATE D-PG OFFICIAL STATUS

05/01/2015 3219 Introduction and first reading Referred to Health, Human Services and Housing

1.1 1.2

1.3

| 1.4<br>1.5 | dysphoria; amending Minnesota Statutes 2014, section 256B.0625, subdivision 3a, by adding a subdivision. |
|------------|--|
| 1.6        | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:  |
| 1.7        | Section 1. Minnesota Statutes 2014, section 256B.0625, subdivision 3a, is amended to                     |
| 1.8        | read:  |
| 1.9        | Subd. 3a. Sex reassignment surgery Treatment of gender dysphoria. Sex                                    |
| 1.10       | reassignment surgery is not covered, unless medically necessary.   |
|            |  |
| 1.11       | Sec. 2. Minnesota Statutes 2014, section 256B.0625, is amended by adding a                               |
| 1.12       | subdivision to read:   |
| 1.13       | Subd. 13k. Treatment of gender dysphoria. Notwithstanding subdivision 13d,                               |
| 1.14       | paragraph (b), clause (1), the commissioner may include within the drug formulary                        |
| 1.15       | established under subdivision 13d, drugs for the treatment of gender dysphoria if:                       |
| 1.16       | (1) the drug is approved for marketing by the United States Food and Drug                                |
| 1.17       | Administration;  |
| 1.18       | (2) the dose and indication for use of the drug is recommended by a clinical guideline                   |
| 1.19       | or practice parameter included in the National Guideline Clearinghouse maintained by                     |
| 1.20       | the United States Department of Health and Human Services Agency for Healthcare                          |
| 1.21       | Research and Quality (AHRQ); and   |
| 1.22       | (3) there is not another drug or regimen available within the formulary to treat                         |
| 1.23       | the condition.   |

Sec. 2.